Pulmonary arterial hypertension: Current diagnosis and management

ACC Current Journal Review

Volumn 11, Issue 3, 2002, Pages 17-21

  McLaughlin, Vallerie V ^a,b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMLODIPINE; ANTICOAGULANT AGENT; ANTINUCLEAR ANTIBODY; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; GLIBENCLAMIDE; ILOPROST; NIFEDIPINE; NITROUS OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN SYNTHASE; UNIPROST; VASODILATOR AGENT; VERAPAMIL; WARFARIN;

ANEMIA; ANGINA PECTORIS; ASCITES; CONTROLLED STUDY; DIAGNOSTIC TEST; DIARRHEA; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ECHOCARDIOGRAPHY; EDEMA; ELECTROCARDIOGRAPHY; FATIGUE; FLUSHING; FOOT DISEASE; HEADACHE; HEART CATHETERIZATION; HEART HEMODYNAMICS; HUMAN; INJECTION PAIN; JAW DISEASE; LIVER DYSFUNCTION; LUNG ANGIOGRAPHY; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; LUNG HEMODYNAMICS; LUNG SCINTISCANNING; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; LUNG VENTILATION PERFUSION RATIO; NAUSEA; PULMONARY HYPERTENSION; REVIEW; SEROLOGY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; STOMACH DISEASE; SYMPTOMATOLOGY; SYNCOPE; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREADMILL EXERCISE; VASOCONSTRICTION; VASODILATATION; WEIGHT REDUCTION;

EID: 0036072673     PISSN: 10621458     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1062-1458(02)00593-7     Document Type: Review

References (6)

1. Rich S, Dantzker RS, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216–23.
2. Rich S, Kaufman E, Levy P. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76.
3. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296–301.
4. McLaughlin V, Genthner D, Panella M, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273–7.
5. Badesch D, Tapson V, McGoon M et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med 2000;132:425–34.
6. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin receptor antagonist Bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2002; (in press).